What diseases is tazetostat mainly used to treat?

Tazemetostat is a new type of epigenetic regulation drug. Its main target is EZH2 enzyme. It has a clear positioning in the field of cancer treatment. It is currently approved for the treatment of two types of malignant tumors that are more specific but difficult to clinically treat: one is follicular lymphoma with EZH2 gene mutations (FL; non-Hodgkin lymphoma), and the other is epithelioid sarcoma (ES; soft tissue sarcoma). Both types of diseases are rare tumors and often have no obvious symptoms in the early stages. They are often in advanced or metastatic states when diagnosed, and treatment options are limited. The emergence of tazerestat provides a new treatment path for these patients.

In follicular lymphoma,EZH2 mutations are believed to be closely related to mechanisms such as tumor cell proliferation and evasion of immune clearance. By selectively inhibiting the activity of this enzyme, tazerestat blocks the development path of cancer cells at the molecular level, achieving disease control and even partial remission. Especially for patients who have failed two or more previous systemic therapies, this drug has become an important later-line treatment option.

In epithelioid sarcoma, tazerestat is suitable for patients who are unresectable or have metastasized. This rare soft tissue sarcoma is known for its aggressive nature, high recurrence rate, and poor response to traditional treatments. Because this type of tumor usually has INI1 deletion and EZH2 activity is abnormally elevated in this background, tazerestat has a unique anti-cancer effect in this type of patients and has become a targeted therapy option specially approved by the FDA.

In addition to these two clear indications, some studies are currently exploring the potential application of tazerestat in other solid tumors with high EZH2 expression, such as prostate cancer, liver cancer and even brain tumors. Although it has not yet been included in formal guidelines, this indicates that its scope of indications is expected to be further expanded. For patients, genotyping testing will become a key criterion for determining whether they are suitable for taking the drug.

Reference materials:https://www.tazverik.com/